Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in Advanced NRG1-Rearranged Malignancies
NCT04410653Phase 2Completed
- Sponsor
- German Cancer Research Center
- Start
- Jul 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of afatinib in pancreatic adenocarcinoma (PDAC), Invasive mucinous adenocarcinoma of the lung (IMA), solid tumor, sponsored by German Cancer Research Center. Started Jul 2022; status: completed.
02
Drugs
afatinib
03
Conditions
pancreatic adenocarcinoma (PDAC)Invasive mucinous adenocarcinoma of the lung (IMA)solid tumor
Beyond the preview
Go deeper on NCT04410653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04410653.